Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An adaptive, pivotal phase II/III trial of SM-88 in combination with gemcitabine (Gemzar) and nab-paclitaxel (Abraxane) in patients with Advanced pancreatic cancer

Trial Profile

An adaptive, pivotal phase II/III trial of SM-88 in combination with gemcitabine (Gemzar) and nab-paclitaxel (Abraxane) in patients with Advanced pancreatic cancer

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Racemetyrosine (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Precision Promise
  • Sponsors Tyme Technologies
  • Most Recent Events

    • 04 Nov 2019 According to a Tyme Technologies media release, the first site for the trial is expected to open by year end 2019.
    • 03 Apr 2019 According to a Tyme Technologies media release, the company in partnership with the Pancreatic Cancer Action Network expected to initiate this study in mid-2019.
    • 25 Feb 2019 According to a Tyme Technologies media release, based on the FDA's feedback, as well as ongoing discussions with the TYME Pancreatic Medical Advisory Board, the company is in the process of finalizing a randomized pivotal trial protocol with a primary endpoint of overall survival.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top